Researchers at Baylor College of Medicine, working with other institutions, have made a breakthrough in understanding how ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

2024年11月22日，Acta Pharmaceutica Sinica B杂志以封面文章的形式报道清华大学药学院尹航课题组最新研究成果“Targeting toll-like receptor 7 as a therapeutic development strategy for systemic lupus erythematosus” ...

1 Department of Oral and Maxillofacial Diseases, Tampere University Hospital, Tampere, Finland 2 Department of Neurosurgery, Tampere University Hospital, Tampere, Finland 3 Department of Forensic ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

A total of ₹2.4 lakh crore has been collected as user fees at toll plazas across India’s national highways since the inception of toll collection, according to recent data presented in the Lok ...

全文刊载于《中华胰腺病杂志》2024年 第24卷 第5期 387-392页全文阅读急性胰腺炎（AP）是多种病因导致胰酶在胰腺内被异常激活后引起胰腺组织自身消化、水肿、出血甚至坏死的炎症反应，其中绝大部分为自限性的轻症急性胰腺炎（mild acute ...

first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of ...